Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jun 6;11:5243–5254. doi: 10.2147/CMAR.S196355

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Chen et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

ELF-1 overexpression promoted NPC proliferation. (A and D) Western blot analyzed the ELF-1 expression in ELF-1-TW01 and ELF-1-TW04 cells. β-actin was used as the loading control. (B and E) Cell growth of ELF-1 NPC transfectants was assayed using the MTT assay. (C and F) The BrdU incorporation assay was performed to assess the proliferation of ELF-1 transfectants and the vehicle control. The results are expressed as the mean±SD of triplicate wells in three independent experiments. *p<0.05; **p<0.01; ***p<0.001.

Abbreviations: BrdU, bromodeoxyuridine; MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NPC, nasopharyngeal carcinoma; SD, standard deviation.